<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019434</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-26082-22081</org_study_id>
    <secondary_id>EORTC-26082</secondary_id>
    <secondary_id>EORTC-22081</secondary_id>
    <secondary_id>EU-20987</secondary_id>
    <secondary_id>2008-003003-31</secondary_id>
    <nct_id>NCT01019434</nct_id>
  </id_info>
  <brief_title>Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma</brief_title>
  <official_title>Radiation Therapy and Concurrent Plus Adjuvant Temsirolimus (CCI-779) Versus Chemo-Irradiation With Temozolomide in Newly Diagnosed Glioblastoma Without Methylation of the MGMT Gene Promoter - A Randomized Multicenter, Open-Label, Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may&#xD;
      stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs&#xD;
      used in chemotherapy, such as temozolomide, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. It is not yet&#xD;
      known whether radiation therapy is more effective when given together with temsirolimus or&#xD;
      temozolomide in treating patients with glioblastoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving radiation therapy together with&#xD;
      temsirolimus to see how well it works compared with giving radiation therapy together with&#xD;
      temozolomide in treating patients with newly diagnosed glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Document the activity profile of temsirolimus by the evaluation of overall survival at 1&#xD;
           year in patients with newly diagnosed glioblastoma multiforme, without methylation of&#xD;
           the MGMT gene promoter, treated with temsirolimus before and concomitantly with&#xD;
           radiotherapy, followed by temsirolimus maintenance therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Investigate safety and tolerability of this therapy regimen in these patients.&#xD;
&#xD;
        -  Assess progression-free survival and overall survival of these patients.&#xD;
&#xD;
        -  Assess biomarkers in the tumor tissue relevant to temsirolimus and disease state, and&#xD;
           their correlation to clinical outcome in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to institution, age&#xD;
      in years (&lt; 50 vs ≥ 50), Karnofsky performance status (PS) (&lt; 80% vs ≥ 80%) OR ECOG PS (0 or&#xD;
      1 vs 2), and corticosteroid use (yes vs no). Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5 days&#xD;
           a week for 6 weeks and receive oral temozolomide concurrently once daily for 6 weeks.&#xD;
           Beginning 4 weeks after completion of concurrent chemoradiotherapy, patients receive&#xD;
           adjuvant oral temozolomide once daily on days 1-5. Treatment with adjuvant temozolomide&#xD;
           repeats every 28 days for up to 12 courses in the absence of disease progression and&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Within 7 weeks after surgery or open biopsy, patients undergo radiotherapy 5&#xD;
           days a week for 6 weeks. Patients also receive temsirolimus IV over 30-60 minutes once&#xD;
           weekly beginning 7 days before initiation of radiotherapy. After completion of&#xD;
           chemoradiotherapy, patients receive maintenance temsirolimus IV once weekly in the&#xD;
           absence of disease progression and unacceptable toxicity.&#xD;
&#xD;
      Frozen tumor biopsies or paraffin-embedded tumor material obtained from surgery or open&#xD;
      biopsy and blood samples are collected for analysis of molecular markers, determination of&#xD;
      the methylation status of the MGMT gene promoter (before randomization and at a later time),&#xD;
      and other studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of worst Adverse Events or Laboratory Event grades as measured by CTCAEs Version 4.0 criteria</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) probability at 6 months and at 12 months, and overall survival (OS) probability at 2 years</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between biomarkers relevant to temsirolimus and PFS and OS</measure>
    <time_frame>end of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Temozolomide</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <description>TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.</description>
    <arm_group_label>Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.</description>
    <arm_group_label>Temsirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed (by open brain biopsy or from a neurosurgical resection of&#xD;
             the tumor) supratentorial glioblastoma multiforme (GBM)&#xD;
&#xD;
               -  WHO grade IV disease&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
          -  Must provide demonstration of an unmethylated MGMT-promoter&#xD;
&#xD;
          -  At least 2 weeks and no more than 6 weeks since surgery or open biopsy&#xD;
&#xD;
          -  Tumor tissue specimens (paraffin-embedded and/or frozen) from the GBM surgery or open&#xD;
             biopsy must be available for central pathology review, MGMT status determination, and&#xD;
             exploratory analysis of PI3-K/Akt/mTOR targets (P70S6K)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  WBC ≥ 3.0 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 75.0 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times the upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 x ULN&#xD;
&#xD;
          -  AST and/or ALT ≤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  PT and PTT normal&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use highly effective contraception&#xD;
&#xD;
          -  No ischemic heart disease in the past 6 months&#xD;
&#xD;
          -  12-lead ECG normal&#xD;
&#xD;
          -  No history of stroke&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated carcinoma in&#xD;
             situ of the cervix or nonmelanoma skin cancer (with no subsequent evidence of&#xD;
             recurrence)&#xD;
&#xD;
          -  No serious concurrent systemic disorder including any of the following that, in the&#xD;
             opinion of the investigator, would compromise the patient's ability to adhere to the&#xD;
             protocol:&#xD;
&#xD;
               -  Active infection&#xD;
&#xD;
               -  HIV infection&#xD;
&#xD;
               -  Cardiac disease&#xD;
&#xD;
               -  QTc prolongation &gt; 450/470 msec (males/females)&#xD;
&#xD;
               -  No patients with a congenital long-QT-syndrome in their own or family medical&#xD;
                  history, unless eligible at the investigator's discretion&#xD;
&#xD;
          -  No known hypersensitivity to the study treatment&#xD;
&#xD;
          -  No known hypersensitivity to antihistamines or other medical reason that prohibits the&#xD;
             intake of antihistamines&#xD;
&#xD;
          -  No current alcohol dependence or drug abuse&#xD;
&#xD;
          -  No legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Able to undergo a gadolinium-enhanced MRI of the brain&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior and no concurrent investigational agent&#xD;
&#xD;
          -  No prior stereotactic biopsy&#xD;
&#xD;
          -  At least 30 days since prior drug therapy that has not received regulatory approval&#xD;
             for any indication&#xD;
&#xD;
          -  No chemotherapy within the past 5 years&#xD;
&#xD;
          -  No prior chemotherapy for a brain tumor&#xD;
&#xD;
          -  No prior radiotherapy to the head&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent anticoagulation therapy except low-dose prophylactic low molecular&#xD;
             weight heparin&#xD;
&#xD;
          -  Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose&#xD;
             for ≥ 1 week&#xD;
&#xD;
          -  At least 14 days since prior and no concurrent enzyme-inducing anticonvulsants (e.g.,&#xD;
             carbamazepine, phenobarbital, and phenytoin)&#xD;
&#xD;
          -  No concurrent strong inducers or inhibitors of CYP3A4&#xD;
&#xD;
          -  No concurrent planned surgery for other diseases (e.g., dental extraction)&#xD;
&#xD;
          -  No placement of Gliadel® wafer during prior surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Wick</last_name>
    <role>Study Chair</role>
    <affiliation>Universitatsklinikum Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianfranco Pesce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>FR 75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>DE 79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>I-40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden - Westeinde</name>
      <address>
        <city>Den Haag</city>
        <zip>NL 2501</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - Daniel den Hoed Cancer Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>NL 3008</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Badalona - Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>ES 08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>July 6, 2018</last_update_submitted>
  <last_update_submitted_qc>July 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

